EORTC phase II study of daily oral linomide in metastatic renal cell carcinoma patients with good prognostic factors

European Journal of Cancer Part A

Volumn 33, Issue 3, 1997, Pages 493-495

  De Wit, R ^a   Pawinsky, A ^b   Stoter, G ^a   Van Oosterom, A T ^c   Fossa S D ^d   Paridaens, R ^e   Svedberg, A ^f   De Mulder, P H M ^g  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b EORTC DATA CENTER   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f PFIZER INC   (United States)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

immunotherapy; linomide; renal cell carcinoma

Indexed keywords

ROQUINIMEX;

ARTHRALGIA; ARTICLE; CANCER IMMUNOTHERAPY; FATIGUE; KIDNEY CARCINOMA; METASTASIS; MYALGIA; NEUROPATHY; PERICARDITIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 17644431683     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)89027-2     Document Type: Article

References (8)

1. Kalland T, Alm G, Stålhandske T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol. 134:1985;3956-3961.
2. Tarkowski A, Gunnarsson K, Nilsson L-A, et al. Successful treatment of autoimmunity in MRL/1 mice with LS 2616, a new immunomodulator. Arthritis Rheum. 29:1986;1405-1409.
3. Larsson E-L, Joki A, Stålhandske T. Mechanism of action of the new immunomodulator LS 2616 on T-cell responses. Int J Immunopharmacol. 9:1987;425-431.
4. Kalland T. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res. 46:1986;3018-3022.
5. Stålhandske T, Eriksoo E, Sandberg B-M. A novel quinoline-carboxamide with interesting immunomodulatory activity. Int J Immunopharmacol. 4:1982;336-341.
6. Pawinsky A, van Oosterom AT, de Wit R, et al. An EORTC phase II study of the efficacy and safety of linomide in the treatment of renal cell carcinoma. Eur J Cancer. 33:1997;496-499.
7. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 48:1988;7310-7313.
8. Palmer PA, Vinke J, Philip T, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol. 3:1992;475-480.